对晚期食道癌的第一线治疗:有效性,安全性和临床影响
Fei Yan1, Jingni Zhu1, Qibing Wu2
1Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Frontiers in medicine
|August 22, 2025
概括
在食道癌症患者中,一线塞普鲁利马布加化学疗法显示有效. 这项实践研究证实了它在不同患者群体中的安全性和有效性.
科学领域:
- 癌症学
- 免疫疗法
- 胃肠道瘤学
背景情况:
- 消化道癌仍然是一个全球性的健康挑战.
- 在PD- L1阳性食道状细胞癌 (ESCC) 的临床试验中,一线治疗塞普鲁利马布加上化疗已显示出有效性.
- 需要现实数据来评估具有不同特征的更广泛患者群体的结果.
研究的目的:
- 评估局部晚期或转移性食道癌症患者的第一线治疗结果.
- 评估基于塞普鲁利马布的治疗方案的有效性 (无进展的生存率,客观反应率,疾病控制率,总生存率) 和安全性.
- 为了解决证据缺陷,并支持在多样化的患者群体中使用塞普鲁利马布.
主要方法:
- 这是一项多中心实验,对接受一线塞普鲁利马布治疗的局部晚期或转移性食道癌症患者进行实验.
- 数据收集包括患者人口统计,治疗细节 (化疗,向治疗,放射治疗) 和临床结果.
- 评估的主要结果是现实无进展生存率 (rwPFS),客观反应率 (ORR),疾病控制率 (DCR),总生存率 (OS) 和安全性.
主要成果:
- 这项研究包括104名患者,其中93. 3%接受化疗.
- 确定的ORR为40. 0%和DCR为97. 8%.
- 中位数rwPFS为12.00个月,1年的生存率为73.5%. 年龄≥65岁的患者显示PFS延长 (12. 00 vs 6. 87个月,p=0. 022).
- 仅报告了两个严重的不良事件,表明了良好的安全性.
结论:
- 这项实验研究证实了基于serplulimab的疗法作为食道癌的第一线治疗方案的有效性和安全性.
- 无论组织类型和PD- L1表达如何,Serplulimab在广泛的患者中显示出临床益处.
- 这些发现强化了塞普鲁利马布在治疗局部晚期或转移性食道癌症方面的价值.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
相关概念视频
02:49Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
935
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
935
01:21Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870